ZIOPHARM Oncology Stock Quote ZIOP - Stock Price, News, Charts, Message Board, Trades

Register for streaming realtime charts, analysis tools, and prices.

Get Started

Home
Investing
Stocks
USA
NASDAQ
ZIOPHARM Oncology Inc (ZIOP) Quote

ZIOPHARM Oncology Inc (ZIOP)

0.8657

0.00

(0.00%)

Closed November 06 4:00PM

Delayed by 15 minutes

0.00

0.00

(0.00%)

After Hours: -

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Current Price

0.8657

Bid

0.865

Ask

0.97

Volume

-

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

Previous Close

0.8657

Open

-

Last Trade

Last Trade Time

Financial Volume

-

VWAP

-

Average Volume (3m)

-

Shares Outstanding

240,627,000

Dividend Yield

-

PE Ratio

-14.79

Earnings Per Share (EPS)

-0.15

Revenue

303k

Net Profit

-35.14M

ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner I... ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad. Show more

Sector

Pharmaceutical Preparations

Industry

Spec Outpatient Facility,nec

Website

www.ziopharm.com

Headquarters

Wilmington, Delaware, USA

Founded

2016

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2...

Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting

HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential...

Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for the third quarter ended September 30, 2021...

Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended...

Ziopharm Oncology to Participate in September Investor Conferences

BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of...

Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions

Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value...

Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates

Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company’s manufacturing facility and presentation of favorable preclinical data Closed venture debt...

Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021

BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to...

Ziopharm Oncology to Participate in Upcoming Conferences

BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor...

Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting

– Highlighted distinctive cellular therapy program, market opportunity and value proposition – Shared optimistic outlook and commitment to deliver value to shareholders – Encouraged by...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CONLGraniteShares ETF Trust GraniteShares	$ 43.12 (61.62%)	25.09M
ARBBARB IOT Group Ltd	$ 0.802709 (42.20%)	227.42M
ELWSEarlyworks Co Ltd	$ 6.00 (41.18%)	6.04M
CTKBCytek Biosciences Inc	$ 7.40 (36.03%)	4.19M
TMCITreace Medical Concepts Inc	$ 7.78 (35.07%)	3.15M
BNOXBionomics Ltd	$ 0.2839 (-42.41%)	17.56M
VSTEVast Renewable Ltd	$ 3.09 (-42.35%)	2.65M
ZCARZoomcar Holdings Inc	$ 7.6899 (-41.74%)	1.33M
ZVSAZyVersa Therapeutics Inc	$ 1.5242 (-39.99%)	2.07M
TNGXTango Therapeutics Inc	$ 3.22 (-37.84%)	14.86M
ELABElevai Labs Inc	$ 0.0173 (-19.16%)	303.44M
NVDANVIDIA Corporation	$ 145.61 (4.07%)	232.47M
ARBBARB IOT Group Ltd	$ 0.802709 (42.20%)	224.6M
SQQQProShares UltraPro Short QQQ	$ 6.6503 (-8.02%)	214.38M
DJTTrump Media and Technology Group Corporation	$ 35.955 (5.94%)	171.54M

DCBill

DCBill 1 minute ago

Happy for all GSE shareholders, but, mighty, ........dead cat bounce!!

See if it can be sustained tomorrow or through the end of the week.
But, I see lots of (very understandable) hope but no evidence

splintered sunlight

splintered sunlight 2 minutes ago

doc2016

doc2016 2 minutes ago

also, in the same vein of msft magnetic -one system......
sounds like 744/ploinks and puddle?'populated with client-secific directives?
8x8 patent by z liu:
Networked device control using a high-level programming interface
Patent number: 11575732
Abstract: Certain

carlson

carlson 2 minutes ago

Stupid question:How bright does the future look from your views?

gdl

gdl 2 minutes ago

I see terminal moves in the dollar and bond yields. that means we should have a nice reversal. if it continues any higher, we breakout and accelerate higher.
Bonds are enemies of the stock market and yet they are moving in sync. I don't know the resistance level or the point the street pani

splintered sunlight

splintered sunlight 2 minutes ago

If we were halted, at least it would stop BBUZ from going down.......

Paulie Cashews

Paulie Cashews 3 minutes ago

Yes, her face is so plastic that when she's done with it, they'll have to cut it up into little pieces, so the birds don't die.

Even Jen Psaki looks like she's had extensive work done recently. Her face looks smoother than the inner-walls of my Real-Doll.

adserv.stocksi

Mojocash

Mojocash 3 minutes ago

Great Job! It's all about the profits! 💰

doc2016

doc2016 4 minutes ago

chatgpt search/ spiders and crawlers and a registry like a card catalogue?.."
.:ChatGPT releases a search engine, an opening salvo in a brewing war with Google for dominance of the AI-powered internet
For decades, Google had an ironclad grip on internet search. Now OpenAI, the startup

frrol

frrol 5 minutes ago

The new data doesn't "change the story", you just had the story wrong. Make sure you understand what a 'mutated' gene means vs the notion of 'wild type'.

And where are you seeing this: "Given that trial subjects with at least one S1R mutation seem to deteriorate fifty percent more at

frrol

frrol 5 minutes ago

The new data doesn't "change the story", you just had the story wrong. Make sure you understand what a 'mutated' gene means vs the notion of 'wild type'.

And where are you seeing this: "Given that trial subjects with at least one S1R mutation seem to deteriorate fifty percent more at

swamp boy

swamp boy 5 minutes ago

Time to contact SEC again and ask them what the F---K is going on.This makes them look like idiots .

splintered sunlight

splintered sunlight 5 minutes ago

rickstereo3333

rickstereo3333 5 minutes ago

Have more been scheduled or is that it re those Sprint Meetings?

Smartypants2

Smartypants2 6 minutes ago

The discovery process will hopefully establish how Auctus specifically follows the toxic lenders business model -- and then resorted to naked shorting. Until then, it's basically "informed speculation" -- which is way more reality-based that most of the conspiracy theries floating around here

crazy horse 0

crazy horse 0 6 minutes ago

Look at CALIF the electoral votes are huge

Amazing she got 226, underperformed Hiden everywhere is what i hear.

MasterBlastr

MasterBlastr 6 minutes ago

Most times a game can show up in the Daily Fantasy main lobby but it isn't available for me to put up in the league.

againstallodds

againstallodds 6 minutes ago

Plain ole mills!!! Absolutely nothing sensible here

That old mill operated for years and was bought for peanuts

Wake up man !!!

Looks like JarRead looking for excuses here, since he can’t geliver the gold.

I’ll give him suggestions:

DR_rugby

DR_rugby 6 minutes ago

The reason for the loss is poor management of cash which they used to settle debt for while negotiating a PPS limit for 400m$ trigger

Thus they are keeping under control with the trigger pony and lower PPS limit by others who buy counterfeit shares

Till the trigger is

bwrbad

bwrbad 6 minutes ago

open2.5 before Thursday market close, open3.0 -3.5 Friday open
interest rate trending back to 2020

janice shell

janice shell 7 minutes ago

Like, where are ya' going to SEND them (if no one out there will TAKE 'em) ?

That is where the "internment camps" come in.

Now what does that plan remind me of?

rooster

rooster 7 minutes ago

Of course I do it’s really not complicated

nowwhat2

nowwhat2 8 minutes ago

I dunno.....but I was wondering.....
Are Republicans , Democrats , or Both "laizze faire" ?
And who was Adam Smith ?
https://en.wikipedia.org/wiki/Adam_Smith
Seen by some as "The Father of Economics" or "The Father of Capitalism" ?

https://www.youtu

bri123

bri123 8 minutes ago

That would be sweet. Need some news from the new guy in a PR to get this moving.

splintered sunlight

splintered sunlight 8 minutes ago

I am seeking funding sources or a monetization program for my bank account in the U.S. with over $600 million in assets in bank accounts. All technical reports and studies are up-to-date. Contact me if you can help or have referrals $splintered sunlight #my bank account

ZIOPHARM Oncology

BNP Paribas Issuance

Delayed Upgrade Clock